Healthcare Triangle Executes Aggressive Growth Strategy, Announcing Within One Week Both $34 Million Planned Acquisition Revenue and Processing of $20 Million in Revenue Generated by Healthcare Providers on Ezovion Platform

Rhea-AI Summary

Healthcare Triangle (Nasdaq:HCTI) announced two near-term commercial developments on October 9–10, 2025 that together aim to accelerate revenue and recurring streams.

The company signed a Letter of Intent to acquire Spain-based Teyame.AI, expected to add roughly $34M in incremental annual revenue and $4.2M in incremental EBITDA. Separately, wholly owned subsidiary QuantumNexis reported the Ezovion EMR platform processed over $20M in end‑user revenue, projected to reach $37M within six months (an 85% increase).

QuantumNexis plans an integrated payment gateway to capture transaction fees, while HCTI cites Q2 2025 revenue of $3.6M (+19% YoY), a full‑year 2025 target of ~$20M, and a committed backlog of $15.8M.

Positive

• $34M estimated incremental annual revenue from Teyame LOI
• $4.2M estimated incremental EBITDA from Teyame integration
• Ezovion processed >$20M end‑user revenue to date
• Projected Ezovion processed revenue of $37M in six months
• Q2 2025 revenue of $3.6M, up 19% year‑over‑year
• $15.8M committed contract backlog providing revenue visibility

Negative

• Teyame transaction announced as a Letter of Intent, not closed
• Integrated payment gateway is not yet launched and remains prospective

Insights

Corporate Growth Strategist

Two near-term deals materially expand revenue mix and create a recurring transaction stream if integration and payment launch proceed as stated.

Healthcare Triangle (HCTI) combines an announced LOI to acquire Teyame.AI (expected to add $34 million of incremental annual revenue and $4.2 million of incremental EBITDA) with QuantumNexis reporting over $20 million processed through the Ezovion EMR and a projection to reach $37 million within six months. Together this transforms revenue composition by adding sizable one-time acquisition revenue and a projected transaction volume that the company intends to monetize via an imminent integrated payment gateway.

The outcomes depend on clear execution milestones: successful closing and integration of Teyame.AI, realization of the stated $4.2 million incremental EBITDA, reliable conversion of Ezovion transaction volume into fee-based recurring revenue once the payment gateway launches, and maintenance of the cited $15.8 million committed contract backlog. Integration complexity, timing risk for the payment gateway, and the accuracy of the projected 85% growth to $37 million are key contingencies.

Watch for three concrete, monitorable items: closing of the Teyame.AI transaction and any disclosed purchase terms (near-term), the formal launch date and commercial terms of the QuantumNexis payment gateway (within the next six months as implied), and subsequent quarterly reports showing whether platform-processed revenue converts into recorded recurring fee revenue versus gross transaction volume; also compare reported EBITDA contribution against the stated $4.2 million figure over the following fiscal year.

Back-to-Back Developments Position Company for Significant Revenue Acceleration and Recurring Revenue Stream

PLEASANTON, CA / ACCESS Newswire / October 10, 2025 / Healthcare Triangle, Inc. (Nasdaq:HCTI), a leader in digital transformation solutions for the healthcare and life sciences industries, has announced two significant developments within the past few days that highlight the company's growing momentum in the AI-powered healthcare technology sector.

In an impressive one-week period, Healthcare Triangle has both signed a Letter of Intent to acquire Spain-based Teyame.AI in a transaction expected to generate approximately $34 million in incremental annual revenue, and announced that its wholly-owned subsidiary QuantumNexis has processed over $20 million in revenue generated by healthcare providers who rely on the Ezovion platform; and the consumption revenue with projections to reach $37 million within six months.

Taken together, these developments signal HCTI's strategic transformation from healthcare IT provider to comprehensive AI-driven digital health innovator with significant revenue scaling across multiple business lines.

Strategic Acquisition Creates Global Patient Engagement Platform

The Teyame.AI acquisition, announced on October 9, represents a pivotal step in HCTI's evolution. The transaction is expected to add approximately $34 million in incremental annual revenue and $4.2 million in incremental EBITDA while positioning the combined entity as a global force in AI-powered patient engagement.

Madrid-headquartered Teyame.AI has built a sophisticated platform that seamlessly blends artificial intelligence with human expertise, currently serving banking and insurance clients while piloting breakthrough healthcare applications.

The company's technology stack includes advanced chatbot automation, multilingual patient engagement tools, and real-time analytics, which are capabilities that become exponentially more powerful when integrated with HCTI's clinical systems.

The strategic acquisition addresses a critical gap in healthcare: the disconnect between advanced clinical systems and meaningful patient interaction.

By combining HCTI's deep healthcare technology expertise with Teyame's proven AI automation platform, the transaction creates an integrated ecosystem where every patient touchpoint becomes intelligent, personalized, and outcome-focused.

Importantly, this acquisition expands the company's reach into international markets and provides its customers with cutting-edge Gen AI solutions.

QuantumNexis Platform Revenue Surges, Payment Gateway Launch Imminent

Just last week, Healthcare Triangle announced that its wholly-owned subsidiary QuantumNexis has achieved a significant milestone, with its Ezovion Electronic Medical Record (EMR) platform processing over $20 million in revenue generated by healthcare providers who rely on the platform to digitize and manage their operations.

As QuantumNexis accelerates its global expansion into India, Bangladesh, Saudi Arabia, and Malaysia, the total revenue processed through the platform by end users is projected to surge to $37 million over the next six months, representing an 85% increase in just half a year.

Perhaps most significantly, QuantumNexis will soon launch its proprietary integrated payment gateway, representing a pivotal evolution in the company's business model. The gateway will enable QuantumNexis to earn a percentage of all revenue processed through the platform, creating a direct, scalable revenue stream from the substantial transaction volume flowing through Ezovion.

By embedding payment processing directly into clinical workflows, QuantumNexis eliminates friction for healthcare providers while capturing recurring transaction-based revenue that scales automatically with platform growth. This effectively positions Healthcare Triangle as a hybrid SaaS + fintech company in the healthcare technology space.

Creating Multiple Value Drivers for Shareholders

The combination of the Teyame acquisition and QuantumNexis milestone creates a compelling multi-faceted growth story for Healthcare Triangle investors:

• Immediate Revenue Expansion: The Teyame acquisition alone is expected to add approximately $34 million in incremental annual revenue and $4.2 million in EBITDA, while QuantumNexis platform revenue generated by healthcare providers is projected to grow from $20M to $37M within six months.

• Recurring Revenue Transformation: The imminent payment gateway launch transforms platform activity into predictable, scalable recurring revenue that grows automatically with platform adoption.

• Strategic Positioning: HCTI is evolving from a healthcare IT provider into a differentiated hybrid SaaS + fintech + AI-powered patient engagement company, creating multiple expansion pathways and appealing to diverse institutional investor bases.

• Global Market Access: The Teyame acquisition provides immediate entry into high-growth European, Middle Eastern, Asia-Pacific, and Latin American markets, while QuantumNexis expansion targets India, Bangladesh, Saudi Arabia, and Malaysia.

• Technology Integration: Teyame's AI automation capabilities integrate seamlessly with existing HCTI platforms including ZILOY (targeting the $448+ billion global mental health market), Ezovion, and Readable.AI, creating powerful network effects and cross-selling opportunities.

• Proven Execution: Both announcements demonstrate HCTI's ability to execute on multiple strategic fronts simultaneously, including organic platform growth, strategic M&A, business model innovation, and international expansion.

"The rapid increase in end-user revenue processed through Ezovion reflects strong adoption and engagement by healthcare providers," said David Ayanoglou. "By launching our payment gateway, HCTI can transform this activity into direct, recurring revenue while driving margin expansion and delivering long-term shareholder value.

Building on Established Momentum

These developments build upon HCTI's already strong operational and financial performance. The company reported Q2 2025 revenues of $3.6 million, representing 19% year-over-year growth, with management targeting approximately $20 million for full-year 2025. HCTI maintains a $15.8 million committed contract backlog providing clear revenue visibility.

HCTI has established strategic partnerships with industry giants including Amazon AWS, Google Cloud, Microsoft Azure, MEDITECH, and EPIC Systems. These are relationships that provide distribution advantages and validate Healthcare Triangle's technology at the highest levels of the industry.
Recent major contract wins with California's top university medical system and Georgia's largest hospital network further demonstrate market traction, while ZILOY's U.S. launch targets mental health needs affecting over 60 million Americans in a global market valued at over $448 billion.

With two major announcements in a single week, Healthcare Triangle, Inc. (Nasdaq:HCTI) is demonstrating the kind of aggressive execution that signals a company in transformation mode.

The $34 million Teyame acquisition expands HCTI's footprint into international markets and creates a comprehensive AI-powered patient engagement platform, while the QuantumNexis milestone and upcoming payment gateway launch help establish a scalable recurring revenue model that positions the company as a unique hybrid SaaS + fintech player in healthcare technology.

These developments build directly on HCTI's existing momentum, including strategic partnerships with Amazon AWS, Google Cloud, and Microsoft Azure; major contract wins with leading healthcare systems; and AI platforms targeting massive underserved markets.

As the company continues executing on multiple fronts simultaneously, Healthcare Triangle is positioning itself as an emerging force in the AI-driven healthcare technology sector with multiple pathways for significant revenue acceleration.

About Healthcare Triangle

Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare organizations including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz^™ and DataEz^™. HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical & business performance optimization.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors out lined in the company's annual report on form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the "SEC") and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Forward-Looking Disclaimer Statements
This article was prepared by Hawk Point Media Group, LLC and may contain information, views, or opinions regarding the future expectations, plans, and prospects of Healthcare Triange, Inc. that constitute or may constitute forward-looking statements. These statements are not historical facts and are based on assumptions, beliefs, and expectations regarding future economic and operating performance. Although Hawk Point Media Group, LLC believes such statements are made in good faith and based on information available at the time of writing, there can be no assurance that the expectations expressed will prove accurate. Healthcare Triange, Inc. and Hawk Point Media Group, LLC undertake no obligation to update or revise any forward-looking statements, except as required by applicable law.

Forward-looking statements are inherently subject to risks, uncertainties, and factors that could cause actual results to differ materially from those projected. Such factors include, but are not limited to, industry conditions, regulatory developments, economic trends, and risks identified in Healthcare Triange, Inc. filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of publication.

Accuracy & Disclosure Statement: Hawk Point Media Group, LLC (HPM) works on a retainer basis with Meza Media Llc. to provide press release, editorial, digital media, and consulting services. Accordingly, Meza Media, Llc. may engage HPM to create content SPONSORED CONTENT relating to multiple public companies during the term of its retainer. Up to ten thousand dollars of the retainer received via wire transfer in USD will be allocated toward the creation and syndication of content about Healthcare Triangle, Inc. Due to this arrangement, this content should be considered sponsored content. The information contained herein is based on sources believed to be reliable, including publicly available filings, company disclosures, and direct website content, and is accurate to the best of our knowledge at the time of creation. This content is for informational purposes only and should not be construed as investment advice. At the time of creation, HPM does not own, buy, sell, or trade securities of the companies covered, including Healthcare Triange, Inc. HPM will not receive award shares as compensation and will NOT purchase shares in the open market for Healthcare Triange, Inc. for a period of not less than thirty days on either side of the engagement period. IF HPM owns shares prior to any services agreement, HPM agrees to either refuse the contract or sell all company shares at least five days before any digital marketing program begins. Any reproduction or syndication of this content must include this statement. This disclosure is made in accordance with Section 17(b) of the Securities Act of 1933, the Federal Trade Commission's Endorsement Guides, and other applicable regulations governing sponsored investment content.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. The publisher does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the Company profiled in the Advertorial here.

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

EMAIL contact: jodymadron@gmail.com

SOURCE: Healthcare Triangle, Inc

View the original press release on ACCESS Newswire

FAQ

What does the Teyame.AI Letter of Intent mean for HCTI (Nasdaq:HCTI)?

HCTI signed an LOI to acquire Teyame.AI, which is expected to add about $34M annual revenue and $4.2M incremental EBITDA if completed.

How much revenue has Ezovion processed for Healthcare Triangle as of October 2025?

QuantumNexis reports the Ezovion EMR platform has processed over $20M in end‑user revenue as of October 10, 2025.

What is the Ezovion revenue projection for the next six months for HCTI?

Healthcare Triangle projects Ezovion’s processed revenue will increase to $37M within six months, an 85% rise from current levels.

How will the upcoming payment gateway affect HCTI’s revenue model?

The planned payment gateway is intended to earn transaction fees on platform volume, creating a recurring, consumption‑based revenue stream for HCTI.

What are HCTI’s recent operating metrics reported for 2025?

HCTI reported Q2 2025 revenue of $3.6M (+19% YoY), a full‑year 2025 target of ~$20M, and a committed backlog of $15.8M.

Is the Teyame acquisition finalized for Healthcare Triangle (HCTI)?

No; the Teyame transaction is currently announced as a Letter of Intent and has not been reported as closed.